Ischemic Central Retinal Vein Occlusion Clinical Trial
Official title:
Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion
The RAVE (Rubeosis Anit-VEgf) trial, utilizes monthly intravitreal Ranibizumab (Lucentis) injections for 9 months to see if total VEGF blockade will prevent neovascular glaucoma and eliminate the need for panretinal photocoagulation in patients with ischemic central retinal vein occlusion.
| Status | Completed |
| Enrollment | 20 |
| Est. completion date | January 2011 |
| Est. primary completion date | January 2011 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 19 Years and older |
| Eligibility |
Inclusion Criteria: - Ability to provide written informed consent and comply with study assessments for the full duration of the study - Age > 18 years - Ischemic CRVO within 3 months of enrollment as per the following inclusion criteria - Three of the following clinical tests must be present to demonstrate ischemic CRVO: - VA 20/200 or worse - RAPD 0.9 LU or worse - Loss of 1-2e isopter on Goldmann Visual field (Kwon et al. 2001) - ERG demonstrating b wave amplitude less than 60% of A wave Exclusion Criteria: - Angle neovascularization greater than 3 clock hours with IOP over 30 (Neovascular glaucoma) - Any previous retinal laser photocoagulation to the study eye - Any previous intravitreal injection in study eye (triamcinolone or other) - Any previous vitrectomy in study eye (posterior or anterior associated with vitreous loss in cataract surgery) - Intracapsular cataract extraction (posterior capsule needs to be present) - Previous history of retinal detachment in study eye - Any previous radiation treatments to head/ neck - Inability to assess iris neovascularization (corneal opacity precluding gonioscopy) - Significant cardiovascular disease or cancer that would prevent follow-up visits or completion of the 12 month study - Significant diabetic retinopathy in the fellow eye (diabetic macular edema, proliferative diabetic retinopathy, or high-risk non-proliferative diabetic retinopathy) - Pregnancy (positive pregnancy test) - Prior enrollment in any study for vein occlusion in the study eye - Participation in another simultaneous medical investigator or trial - Ocular disorders in the study eye that may confound interpretation of study results, including retinal detachment, macular hole, or choroidal neovascularization of any cause (e.g., DME AMD, ocular histoplasmosis, or pathologic myopia) - Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the study period - Aphakia or absence of the posterior capsule in the study eye - Previous violation of the posterior capsule is also excluded unless it occurred as a result of YAG laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation - History of idiopathic or autoimmune uveitis in either eye - Structural damage to the center of the macula in the study eye preexisting to CRVO likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s) - Vitreomacular traction or epiretinal membrane in the study eye evident biomicroscopically or by OCT - Ocular inflammation (including trace or above) in the study eye - Uncontrolled glaucoma (defined as intraocular pressure =30 mm Hg despite treatment with anti- medications) or previous filtration surgery in the study eye - Infectious blepharitis, keratitis, scleritis, or conjunctivitis (in either eye) or current treatment for serious systemic infection - Spherical equivalent of the refractive error in the study eye of more than -8 diopters myopia (For patients who have had refractive or cataract surgery in the study eye, pre-operative spherical equivalent refractive error of more than -8 diopters myopia is not allowed) Systemic Conditions - Uncontrolled Blood pressure exceeding diastolic pressure of 100 mm Hg (sitting) during the screening period - Uncontrolled diabetes mellitus - Renal failure requiring dialysis or renal transplant - Premenopausal women not using adequate contraception - Previous participation in other studies of investigational drugs (excluding vitamins and minerals) within 3 months preceding Day 0 - History of other disease, metabolic dysfunction, physical examination finding, or other findings giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug, might affect interpretation of the results of the study, or render the subject at high risk from treatment complications - INR = 3.0 (e.g. due to current treatment with warfarin). The use of aspirin is not an exclusion. Other - History of allergy to fluorescein, not amenable to treatment - Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality to be analyzed and graded by the central reading center - Inability to comply with study or follow up procedures - History of allergy to humanized antibodies or any component of the ranibizumab formulation |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | Vitreoretinal Consultants | Houston | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| Greater Houston Retina Research |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Preservation of 5Ve isopter Goldmann visual field versus baseline at 1 year | 12 and 24 months | No | |
| Primary | Estimate the % of subjects progressing to neovascular glaucoma requiring pan-retinal photocoagulation or glaucoma surgery after treatment with ranibizumab (comparing 0.3mg to 0.5mg doses) | 12 and 24 mponths | No | |
| Secondary | Assess the systemic and local safety of 0.3mg and 0.5mg of ranibizumab in patients with ischemic CRVO | 12 and 24 months | Yes | |
| Secondary | Assess improvement from baseline in Visual Acuity at 1 year | 12 and 24 months | No | |
| Secondary | Assess the impact on retinal thickness and volume (as measured by OCT) | 12 and 24 months | No | |
| Secondary | Assess the impact of ranibizumab (0.3mg and 0.5mg) on time to improvement in visual acuity | 12 and 24 months | No | |
| Secondary | Asses the impact of ranibizumab (0.3mg and 0.5mg) on time to improvement in retinal thickness | 12 and 24 months | No | |
| Secondary | Asses the impact of ranibizumab (0.3mg and 0.5mg) on percentage of patients developing 3 or more clock hours of rubeosis at 6 and 12 months and 24 months | 6, 12, and 24 months | No | |
| Secondary | Assess the impact of ranibizumab (0.3mg and 0.5mg) on prevention of greater than 3 clock hours rubeosis (as measured by iris fluorescein angiography) | 12 and 24 months | No | |
| Secondary | Assess the impact of ranibizumab on the gain or decrease of area of visual field on 14e Goldman visual field area | 12 and 24 months | No | |
| Secondary | Assess the impact of ranibizumab on b wave component of ERG | 12 and 24 months | No | |
| Secondary | Aqueous VEGF levels | 24 months | No |